Development License. Subject to the terms and conditions set forth herein, Servier hereby grants to Pieris a co-exclusive (with Servier), sublicensable (subject to Section 2.1.3 below), personal and non-transferable Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED (except as set forth in Section 13.5), right and license under the Servier IP (i) to Develop and have Developed (subject to Section 2.3.6), the Lead Product in the Field anywhere in the Pieris Territory and the Servier Territory, including to perform Pieris’ obligations under the Joint Development Plan and to undertake Territory Specific Work and Unsponsored Work as permitted herein, and (ii) (a) to Manufacture, have Manufactured (subject to Section 2.3.6), the Lead Product anywhere in the Pieris Territory and the Servier Territory, and (b) to import the Lead Product into the Servier Territory and the Pieris Territory, in each case (clause (a) and (b)), solely for such Development; provided that with respect to any Servier Building Block IP within the Servier IP, the foregoing license under this Section 2.1.2.(a) shall be non-exclusive.
Appears in 1 contract
Samples: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)
Development License. Subject to the terms and conditions set forth herein, during the Term following PCC for a given CoDev Collaboration Product, Servier hereby grants to Pieris a co-exclusive (with Servier), sublicensable (subject to Section 2.1.3 below3.2.4), personal and non-transferable (except as set forth in Section 13.5), right and license under the Servier IP (1) to Develop and have Developed (subject to Section 3.1.4 and Section 2.3.6), and use the CoDev Collaboration Product in the Field anywhere in the Pieris Territory and the Servier Territory, including to perform Pieris’ obligations under the Collaboration Plan and to undertake Territory Specific Work and Unsponsored Work as permitted herein, and (2) (a) to Manufacture and have Manufactured (subject to Section 3.4 and Section 2.3.6), the CoDev Collaboration Product in the Field anywhere in the Pieris Territory and the Servier Territory, and (b) to import, have imported, export and have exported the CoDev Collaboration Product into the Servier Territory and the Pieris Territory, in each case (clause (a) and (b)), solely for such Development; provided that with respect to any Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED (except as set forth in Section 13.5), right and license under the Servier IP (i) to Develop and have Developed (subject to Section 2.3.6), the Lead Product in the Field anywhere in the Pieris Territory and the Servier Territory, including to perform Pieris’ obligations under the Joint Development Plan and to undertake Territory Specific Work and Unsponsored Work as permitted herein, and (ii) (a) to Manufacture, have Manufactured (subject to Section 2.3.6), the Lead Product anywhere in the Pieris Territory and the Servier Territory, and (b) to import the Lead Product into the Servier Territory and the Pieris Territory, in each case (clause (a) and (b)), solely for such Development; provided that with respect to any Confidential Servier Building Block IP within the Servier IP, the foregoing license under this Section 2.1.2.(a3.2.3.(b)(i) shall be non-exclusive.
Appears in 1 contract
Samples: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)
Development License. Subject to the terms and conditions set forth herein, Servier Pieris hereby grants to Pieris Servier during the Term following PCC for a given CoDev Collaboration Product, a co-exclusive (with ServierPieris), sublicensable (subject to Section 2.1.3 3.2.4 below), personal and non-transferable (except as set forth in Section 13.5), right and license under the Pieris IP (1) to Develop and have Developed (subject to Section 3.1.4 and Section 2.3.6), and use the CoDev Collaboration Product in the Field anywhere in the Pieris Territory and the Servier Territory, including to perform Servier’s obligations under each Collaboration Plan and to Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED Confidential undertake Territory Specific Work and Unsponsored Work as permitted herein, and (except as set forth in Section 13.5), right and license under the Servier IP 2) (iA) to Develop Manufacture and have Developed Manufactured (subject to Section 3.4 and Section 2.3.6), the Lead CoDev Collaboration Product in the Field anywhere in the Pieris Territory and the Servier Territory, including to perform Pieris’ obligations under the Joint Development Plan and to undertake Territory Specific Work and Unsponsored Work as permitted herein, and (ii) (aB) to Manufactureimport, have Manufactured (subject to Section 2.3.6)imported, export and have exported the Lead Product anywhere in the Pieris Territory and the Servier Territory, and (b) to import the Lead CoDev Collaboration Product into the Servier Territory and the Pieris Territory, in each case (clause (aA) and (bB)), solely for such Development; provided that with respect to any Servier Pieris Building Block IP within the Servier Pieris IP, the foregoing license under this Section 2.1.2.(a3.2.3.(a)(i) shall be non-exclusive.
Appears in 1 contract
Samples: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)
Development License. Subject to the terms and conditions set forth herein, during the Term following [***] for a given CoDev Collaboration Product, Servier hereby grants to Pieris a co-exclusive (with Servier), sublicensable (subject to Section 2.1.3 below3.2.4), personal and non-transferable (except as set forth in Section 13.5), right and license under the Servier IP (1) to Develop and have Developed (subject to Section 3.1.4 and Section 2.3.6), and use the CoDev Collaboration Product in the Field anywhere in the Pieris Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED (except as set forth in Section 13.5), right and license under the Servier IP (i) to Develop and have Developed (subject to Section 2.3.6), the Lead Product in the Field anywhere in the Pieris Territory and the Servier Territory, including to perform Pieris’ obligations under the Joint Development Collaboration Plan and to undertake Territory Specific Work and Unsponsored Work as permitted herein, and (ii2) (a) to Manufacture, Manufacture and have Manufactured (subject to Section 3.4 and Section 2.3.6), the Lead CoDev Collaboration Product in the Field anywhere in the Pieris Territory and the Servier Territory, and (b) to import import, have imported, export and have exported the Lead CoDev Collaboration Product into the Servier Territory and the Pieris Territory, in each case (clause (a) and (b)), solely for such Development; provided that with respect to any Servier Building Block IP within the Servier IP, the foregoing license under this Section 2.1.2.(a3.2.3.(b)(i) shall be non-exclusive.
Appears in 1 contract
Samples: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)
Development License. Subject to the terms and conditions set forth herein, Servier Pieris hereby grants to Pieris Servier during the Term following [***] for a given CoDev Collaboration Product, a co-exclusive (with ServierPieris), sublicensable (subject to Section 2.1.3 3.2.4 below), personal and non-transferable (except as set forth in Section 13.5), right and license under the Pieris IP (1) to Develop Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED (except as set forth in Section 13.5), right and license under the Servier IP (i) to Develop and have Developed (subject to Section 3.1.4 and Section 2.3.6), and use the Lead CoDev Collaboration Product in the Field anywhere in the Pieris Territory and the Servier Territory, including to perform Pieris’ Servier’s obligations under the Joint Development each Collaboration Plan and to undertake Territory Specific Work and Unsponsored Work as permitted herein, and (ii2) (aA) to Manufacture, Manufacture and have Manufactured (subject to Section 3.4 and Section 2.3.6), the Lead CoDev Collaboration Product in the Field anywhere in the Pieris Territory and the Servier Territory, and (bB) to import import, have imported, export and have exported the Lead CoDev Collaboration Product into the Servier Territory and the Pieris Territory, in each case (clause (aA) and (bB)), solely for such Development; provided that with respect to any Servier Pieris Building Block IP within the Servier Pieris IP, the foregoing license under this Section 2.1.2.(a3.2.3.(a)(i) shall be non-exclusive.
Appears in 1 contract
Samples: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)
Development License. Subject to the terms and conditions set forth herein, Servier hereby grants to Pieris a co-exclusive (with Servier), sublicensable (subject to Section 2.1.3 below), personal and non-transferable Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED (except as set forth in Section 13.5), right and license under the Servier IP (i) to Develop and have Developed (subject to Section 2.3.6), the Lead Product in the Field anywhere in the Pieris Territory and the Servier Territory, including to perform Pieris’ obligations under the Joint Development Plan and to undertake Territory Specific Work and Unsponsored Work as permitted herein, and (ii) (a) to Manufacture, have Manufactured (subject to Section 2.3.6), the Lead Product anywhere in the Pieris Territory and the Servier Territory, and (b) to import the Lead Product into the Servier Territory and the Pieris Territory, in each case (clause (a) and (b)), solely for such Development; provided that with respect to any Servier Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential Building Block IP within the Servier IP, the foregoing license under this Section 2.1.2.(a) shall be non-exclusive.
Appears in 1 contract
Samples: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)